|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
B-cell chronic lymphocytic leukemia (B-CLL) is a clinically variable disease where mutations in DNA damage response genes ATM or TP53 affect the response to standard therapeutic agents.
|
15692065 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
CTD_human |
CLL with 11q deletion can be divided into two subgroups based on the integrity of the residual ATM allele.
|
17968022 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
CLL with 11q deletion can be divided into two subgroups based on the integrity of the residual ATM allele.
|
17968022 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM mutations are also involved in the development of sporadic human cancers such as T-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
|
10738255 |
2000 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
LHGDN |
ATM mutations in B-cell chronic lymphocytic leukemia.
|
14754616 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
|
24584352 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).
|
27588518 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.
|
21955805 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
A robust response to ODN+IL-15 was positively linked to presence of chromosomal anomalies (trisomy-12 or ataxia telangiectasia mutated anomaly + del13q14) and negatively linked to a very high proportion of CD38(+) cells within the blood-derived B-CLL population.
|
26136429 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities in ATM and TP53 genes represent important predictive factors in chronic lymphocytic leukemia (CLL); however, the efficacy of CD20 targeting immunotherapy is only poorly defined in the affected patients.
|
24970561 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the tumor-suppressor gene ATM in the consensus deletion region was found to be biallelically inactivated in about one third of B-CLL cases, in the majority of those who have this deletion, inactivation of the remaining ATM allele was not observed.
|
15543602 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among the 509 CLL cases 349 (68.6%) had FISH (4-probe panel) abnormalities: 160 del 13q [45.8% (122-del 13q, 18-biallelic del 13q, 20-monoallelic/biallelic del 13q)], 71 tri 12 (20.3%), 17 del ATM (5%), 12 del p53 (3.4%) and 89 > or = 2 FISH abnormalities (25.5%).
|
16487171 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
An additional 111 cases of B-CLL were studied for expression of ATM protein by Western blot analysis and RIA.
|
9788599 |
1998 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Array comparative genomic hybridization testing was performed on 55 cases of CLL in addition to a standard panel of FISH probes (ATM on 11q22, trisomy 12, 13q14, p53 on 17p13).
|
21143592 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
At the clinically relevant concentration of fludarabine, TP53-abnormal samples exhibited markedly higher resistance to fludarabine than the remaining CLL samples (P = 0.012); cohort with ATM deletion was not more resistant than wt cells.
|
19018867 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Based on this, we propose that one molecular mechanism by which 11q23 deletions confer a poor prognosis in CLL is via increased TfR expression secondary to ATM loss, resulting in the increased cellular iron import, and hence increased capacity for malignant growth.
|
16326028 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
|
23091097 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
CC abnormality rates were also compared to fluorescence in situ hybridization (FISH) results using probes for CLL (LSI D13S319/13q34/CEP 12: LSI ATM/p53).
|
20362231 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
|
26837699 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined imaging/ fluorescence-in-situ hybridization performed in four SM-AHNMD cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-CMML and one patient with SM-MDS, but not in the mast cells of a case SM-associated with chronic lymphocytic leukemia with ATM-deletion.
|
23440662 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consequently, the greater severity of the TP53-mutant B-CLLs compared with ATM-mutant B-CLLs is consistent with the additive effect of defective apoptotic and elevated survival responses after DNA damage in these tumors.
|
12958068 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Considering the aberrations in the ATM gene in CLL and the high rate of incidence of lymphoid neoplasias in AT patients, the authors investigated its incidence rate and significance in patients with adult acute lymphoblastic leukemia (ALL).
|
10699895 |
2000 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
|
15193446 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA repair (e.g., mutations and/or deletions of the p53, ATM, and p14(ARF) genes and epigenetic silencing of the MLH1 gene).
|
16053658 |
2005 |